NCT01396239已完成2 期
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Efficacy, Safety, Tolerability and Pharmacokinetics Study of AVI-4658(Eteplirsen),in the Treatment of Ambulant Subjects With Duchenne Muscular Dystrophy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Change in the Number (%) of Dystrophin Positive Fibers
研究概览
简要总结
This study is designed to assess the efficacy, safety, tolerability, and pharmacokinetics (PK) of AVI-4658 (eteplirsen) in both 50.0 mg/kg and 30.0 mg/kg doses administered over 24 weeks in subjects diagnosed with Duchenne muscular dystrophy (DMD).
详细描述
For details regarding the roll-over extension study 4658-us-202, please refer to NCT01540409.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 7 Years 至 13 Years（Child）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •A subject must meet all of the following criteria to be eligible for this study.
- •Be a male with DMD and have an out-of-frame deletion(s) that may be corrected by skipping exon 51 [e.g., deletions of exons 45-50, 47-50, 48-50, 49-50, 50, 52, 52-63], as confirmed in a Clinical Laboratory Improvement Act-accredited laboratory by any of the peer-reviewed and published methodology that evaluates all exons (including, but not limited to, multiplex ligation-dependent probe, comparative genomic hybridization, and single condition amplification/internal primer analysis).
- •Be between the ages of 7 and 13 years, inclusive.
- •Have stable cardiac function and stable pulmonary function (forced vital capacity [FVC] ≥50% of predicted and not require supplemental oxygen) that, in the Investigator's opinion, is unlikely to decompensate over the duration of the study.
- •Be receiving treatment with oral corticosteroids and have been on a stable dose for at least 24 weeks before study entry. Subjects may be allowed to take other (non-RNA antisense or gene therapy) medication (including angiotensin-converting enzyme [ACE] inhibitors, β blockers, losartan potassium, and coenzyme Q) as long as they have been on a stable dose of the medication for 24 weeks before the screening visit (Visit 1) and the dose will remain constant throughout the study.
- •Have intact right and left biceps muscles or an alternative upper arm muscle group.
- •Achieve an average distance within 200m and 400m ±10% (i.e. within 180m and 440m) while walking independently over six minutes.
- •Have a left ventricular ejection fraction (LVEF) of >40% based on the ECHO that is obtained at the screening visit (Visit 1). A subject who has abnormal ECHO findings but who has an LVEF of >40% may be enrolled in the study at the Investigator's discretion; however, the subject must have been receiving stable doses of ACE inhibitors or β blockers for at least 24 weeks before study entry.
- •Have a parent(s) or legal guardian(s) who is able to understand and comply with the all of the study procedure requirements.
- •Be willing to provide informed assent and have a parent(s) or legal guardian(s) who is willing to provide written informed consent for the subject to participate in the study.
排除标准
- •A subject who meets any of the following criteria will be excluded from this study.
- •Use of any pharmacologic treatment, other than corticosteroids, that might have an effect on muscle strength or function within 12 weeks before study entry (e.g., growth hormone, anabolic steroids).
- •Previous treatment with the experimental agents eteplirsen, BMN-195, or PRO
- •Previous treatment with any other experimental agents or participation in any other DMD interventional clinical study within 12 weeks before entry into this study; including use of the shock training system or "STS," or planned use during this study.
- •Surgery within 3 months before study entry or planned surgery at any time during this study.
- •Presence of other clinically significant illness at the time of study entry, including significant renal dysfunction (as measured by urinary cystatin C, KIM-1, or urinary total protein), or average heart rate during screening Holter monitoring in excess of 110 bpm (unless subsequently treated and confirmed controlled and stable on a β-blocker) or QTc >450 ms.
- •Use of any aminoglycoside antibiotic within 12 weeks before the screening visit (Visit 1) or need for use of an aminoglycoside antibiotic during the study (unless discussed and agreed with the Principal Investigator and medical monitor).
- •Prior or ongoing medical condition that, in the Investigator's opinion, could adversely affect the safety of the subject or that makes it unlikely that the course of treatment or follow-up would be completed or could impair the assessment of study results.
研究组 & 干预措施
AVI-4658 (Eteplirsen)
Experimental
- 50 mg/kg eteplirsen for 28 weeks
- 30 mg/kg eteplirsen for 28 weeks
干预措施: AVI-4658 (Eteplirsen) (Drug)
Placebo / Delayed Treatment
Placebo Comparator
3a. Placebo 50 mg/kg phosphate buffered saline solution identical in appearance to eteplirsen for 24 weeks followed by 50 mg/kg of eteplirsen for 4 weeks.
3b. Placebo 30 mg/kg phosphate buffered saline solution identical in appearance to eteplirsen for 24 weeks followed by 30 mg/kg of eteplirsen for 4 weeks.
干预措施: Placebo (Other)
结局指标
主要结局
Change in the Number (%) of Dystrophin Positive Fibers
时间窗: After 12 weeks for 4 patients who received 50 mg/kg and 2 patients who received placebo. After 24 weeks for 4 patients who received 30 mg/kg and 2 patients who received placebo.
The primary efficacy endpoint will be based on the pre-treatment and post-treatment change in the number (%) of dystrophin positive fibers as measured in the muscle biopsy tissue on immunohistochemistry (IHC).
次要结局
- Change From Baseline: 6 Minute Walk Test (6MWT) - Modified Intent to Treat Population (mITT)(24 weeks)
- Change From Baseline: 6 Minute Walk Test (6MWT) - Intent to Treat Population (ITT)(24 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple SclerosisCentral Neuropathic PainMultiple SclerosisNCT01324232Avanir Pharmaceuticals209
已完成
1 期
Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's DiseaseCentral Nervous System DiseasesAlzheimer's DiseaseNCT00766363FORUM Pharmaceuticals Inc49
已完成
1 期
An Ascending Multiple Dose Study of VTP-38543 in Adult Participants With Mild to Moderate Atopic DermatitisDermatitis, AtopicNCT02655679Vitae Pharmaceuticals, Inc.104
已完成
1 期
A Study of the Efficacy and Safety of Supaglutide in Healthy ParticipantsDiabetes Mellitus, Type 2NCT03745885Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.48
终止
2 期
A Study of RO5186582 in Down Syndrome Among Children 6 to 11 Years of AgeDown SyndromeNCT02484703Hoffmann-La Roche45